JNJ · News · 20260921N

Portfolio Reshaping (M&A / Divestiture)

JOHNSON & JOHNSON · 2026-09-21 · Importance 71 · Surprise 60

Johnson & Johnson announced plans in late 2025 to spin off its orthopedics business. In early 2026, the company was reportedly in discussions with private-equity firms about selling the unit. The potential transaction was valued at approximately $20 billion, indicating a material reshaping of J&J’s MedTech portfolio.

Key facts

• In early 2026, Johnson & Johnson was reported to be in talks with private equity firms about a sale of its orthopedics business. source
• The Caplyta bipolar mania study success comes following Johnson & Johnson's acquisition of Intra-Cellular Therapies. source